TickerFacts.

Chemomab Therapeutics Ltd. (CMMB): Cost of Revenue

Annual figures by period end, from SEC filings.

$2.33M
Year ended 2025-12-31
-23.2%
3-year compound annual growth
$5.14M2021-12-31: $3.31M2022-12-31: $5.14M2023-12-31: $4.39M2024-12-31: $2.46M2025-12-31: $2.33M$2.33M
2021-12-31 Cost of Revenue (USD) 2025-12-31
Period endedCost of RevenueChange YoYSource filing
2025-12-31$2.33M-5.6%2026-03-23, From 2025-01-01
2024-12-31$2.46M-43.9%2026-03-23, From 2024-01-01
2023-12-31$4.39M-14.6%2026-03-23, From 2023-01-01
2022-12-31$5.14M+55.3%2025-04-04, From 2022-01-01
2021-12-31$3.31Mn/a2024-03-28, From 2021-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCost of RevenueChange YoY
Chemomab Therapeutics Ltd. (CMMB)2025-12-31$2.33M-5.6%
NRX Pharmaceuticals, Inc. (NRXP)2025-12-31$505.0Kn/a
PMGC Holdings Inc. (ELAB)2025-12-31$404.8Kn/a
PRF Technologies Ltd. (PRFX)2025-12-31$70.0Kn/a
Aditxt, Inc. (ADTX)2025-12-31$2.9K-99.5%
Impact Biomedical Inc. (IBO)2025-12-31$424.0Kn/a
Clene Inc. (CLNN)2025-12-31$43.0K-38.6%
Longeveron Inc. (LGVN)2025-12-31$396.0K-22.0%
Lftd Partners Inc. (LIFD)2025-12-31$24.30M-1.1%

Compare CMMB, NRXP, ELAB, PRFX side by side · Screen every company in Pharmaceutical Preparations ↗